Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) COO Sells 229 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 229 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $45.59, for a total value of $10,440.11. Following the transaction, the chief operating officer now owns 274,466 shares of the company’s stock, valued at approximately $12,512,904.94. This represents a 0.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total value of $97,426.49.

Twist Bioscience Trading Down 6.0 %

Shares of Twist Bioscience stock traded down $2.89 during trading hours on Tuesday, hitting $45.62. 814,483 shares of the company were exchanged, compared to its average volume of 657,996. The business has a 50-day moving average of $46.16 and a 200-day moving average of $46.51. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of -12.67 and a beta of 1.85.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Barclays lowered their target price on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. TD Cowen reiterated a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Robert W. Baird upped their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $51.90.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB purchased a new position in Twist Bioscience in the third quarter valued at about $34,000. Signaturefd LLC boosted its position in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Twist Bioscience in the second quarter valued at $61,000. Beaird Harris Wealth Management LLC acquired a new stake in Twist Bioscience in the 3rd quarter valued at about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.